HHS
-
“The most effective programs are built on principles that translate across borders,” says Ericka Watson
CEO of Data Strategy Advisors LLC on the shifting compliance landscape of personal data security.
-
DOJ, DEA reclassify marijuana products as Schedule III drugs
The changes move products containing marijuana to a less restrictive category, taking significant strides toward the legalization of the drug itself.
-
GRIP Extra: Regulators lower US community bank leverage ratio, DOJ seizes $700m from scam center
Our in-brief roundup of notable stories from the last week.
-
White House issues executive order to pave way for psychedelic drug treatments
The order, which surprised some legal analysts, will accelerate access to some Schedule I controlled substances to treat patients with serious mental illness.
-
Kennedy signals overhaul of US Preventive Services Task Force
During a heated testimony before the House Committee on Ways and Means, the HSS secretary criticized the task force for a “lackadaisical” approach over two decades.
-
GRIP Extra: OSFI releases Annual Risk Outlook, SEC advances Treasury cash futures cross margining
Our in-brief roundup of notable stories from the last week.
-
FDA to consider relaxing restrictions for peptides
The regulator said it is looking to take seven peptides off a restrictive list for unapproved drugs considered too risky.
-
CMS issues final 2027 Medicare Advantage and Part D Payment Rates
Payor and provider groups are saying the rate increases may not be enough to stave off cuts to coverage.